THERADIAG announced the launch of four additional kits in its i-Tracker? tests range and the validation of a new parameter in the United States, all dedicated to biotherapy monitoring. In addition to its eight kits that have already received CE marking1, Theradiag is expanding its range with 4 more kits of i-Tracker? tests: i-Tracker? Golimumab, i-Tracker? Anti-Golimumab, i-Tracker? Rituximab and i-Tracker? Anti-Rituximab, all of which being adapted to its latest generation random-access analyzer i-Track10? and the IDS-iSYS automated system manufactured by the company IDS.